• Oteseconazole (VT-1161): Selective CYP51 Inhibitor for Candi

  2026-06-02

  Oteseconazole (VT-1161) is a next-generation, selective tetrazole antifungal targeting CYP51 to inhibit ergosterol biosynthesis in Candida species. Its high selectivity for fungal CYP51 over human CYP3A4 reduces drug-drug interactions, offering potent activity against fluconazole-resistant strains and recurrent vulvovaginal candidiasis.

• Prestained Protein Marker (Triple Color): Advanced Utility i

  2026-06-01

  Explore the advanced applications of the Prestained Protein Marker (Triple color, EDTA free, 10-250 kDa) in molecular interaction assays. This article uniquely examines its role in precise protein sizing for mechanistic studies, integrating recent scientific insights for superior lab outcomes.

• PERK–JAK1–STAT3 Axis Drives Pyroptosis in Disc Degeneration

  2026-06-01

  This study uncovers how excessive endoplasmic reticulum stress (ERS) triggers inflammatory pyroptosis in nucleus pulposus cells via the PERK-dependent activation of JAK1–STAT3 signaling. The findings highlight a mechanistic link between ERS and intervertebral disc degeneration, suggesting new therapeutic targets for degenerative disc disease.

• Transcription Termination Regulates DNA Damage After WEE1 In

  2026-05-31

  This study reveals that efficient transcription termination mitigates DNA damage induced by WEE1 inhibition in cancer cells. The findings clarify how transcription-replication conflicts contribute to genome instability and suggest new strategies for cancer therapy via modulation of transcription termination.

• Epalrestat as an Aldose Reductase Inhibitor: Workflow Advanc

  2026-05-30

  Epalrestat uniquely combines potent aldose reductase inhibition with direct KEAP1/Nrf2 pathway activation, enabling advanced experimental modeling in neurodegeneration and diabetic complications. This article provides actionable protocols, troubleshooting insights, and strategic context for oxidative stress and Parkinson’s disease research.

• Topotecan as a Novel Topoisomerase I Inhibitor in Oncology

  2026-05-29

  The reviewed study establishes topotecan as a first-in-class, water-soluble topoisomerase I inhibitor with proven antitumor activity and a distinctive pharmacological profile. Its ability to induce apoptosis via stable DNA/topoisomerase I complexes has advanced treatment options for small cell lung cancer and ovarian cancer, with significant implications for combination regimens and future research directions.

• 3-Deazaneplanocin (DZNep): Applied Workflows in Epigenetic M

  2026-05-29

  3-Deazaneplanocin (DZNep) redefines experimental strategies in cancer and metabolic research by targeting epigenetic pathways with precision. This article delivers actionable protocols, troubleshooting insights, and advanced use-cases to help labs maximize data reliability and translational relevance.

• Açaí Extracts and Drug Metabolism: Cytotoxicity and Inductio

  2026-05-28

  This study systematically investigates the cytotoxic and pharmacokinetic effects of various açaí (Euterpe oleracea) extracts in human hepatocytes. It reveals specific extract-dependent cytotoxicity but minimal induction of major drug-metabolizing enzymes or transporters, refining our understanding of botanical supplement safety and drug interaction risks.

• GSK126 EZH2 Inhibitor: Precision Tool for Cancer Epigenetics

  2026-05-28

  GSK126, a highly selective EZH2 inhibitor, is revolutionizing cancer epigenetics research with its powerful blockade of PRC2-mediated gene silencing. This article delivers actionable workflows, troubleshooting strategies, and translational insights that set GSK126 apart for dissecting EZH2-driven oncogenesis and immune regulation.

• HAUS1 Drives HCC Progression via CDK4 Activation: Mechanisti

  2026-05-27

  This study identifies HAUS1 as a key regulator of CDK4 transcription in hepatocellular carcinoma, showing how HAUS1 overexpression enhances tumor cell proliferation, invasion, and migration. The findings clarify a critical oncogenic pathway, informing future therapeutic strategies and refining cell proliferation assay models.

• PP2A-Driven Autophagy Modulates Candida albicans Biofilm Res

  2026-05-27

  This study reveals that Protein Phosphatase 2A (PP2A) regulates biofilm formation and antifungal drug resistance in Candida albicans by inducing autophagy via ATG protein phosphorylation. The findings provide new mechanistic insight into how autophagy impacts antifungal efficacy, outlining potential molecular targets for overcoming biofilm-associated resistance.

• PreScission Protease (PSP): Technical Guide for Tag Cleavage

  2026-05-26

  PreScission Protease (PSP) enables precise removal of fusion protein tags during purification workflows, minimizing off-target cleavage and preserving protein integrity. PSP is best applied to recombinant proteins containing the HRV 3C recognition site and is most effective under low-temperature conditions. It should not be used for substrates lacking this specific cleavage motif or outside validated buffer systems.

• Patient-Derived 3D Spheroids: A Translational Model for Pros

  2026-05-26

  This study establishes and characterizes patient-derived three-dimensional (3D) spheroid cultures as a robust in vitro model for organ-confined prostate cancer. The model offers new opportunities for translational research, including long-term viability, molecular characterization, and drug response profiling, addressing major gaps in preclinical prostate cancer modeling.

• Cyclo (-RGDfC) in Translational Oncology: Precision Assays a

  2026-05-25

  Explore how Cyclo (-RGDfC), a potent cyclic RGD peptide, empowers translational cancer research through integrin αvβ3 targeting and advanced assay optimization. This article uniquely bridges practical assay design with mechanistic insights and real-world oncology challenges.

• Pandemic Response Box Reveals Antifungal Hits Against Candid

  2026-05-25

  The referenced study systematically screened the MMV Pandemic Response Box to identify compounds with potent inhibitory activity against multidrug-resistant bacterial and clinically relevant fungal isolates, including Candida species. Its findings highlight both promising antifungal candidates and the methodological importance of high-throughput MIC screening for advancing the treatment of resistant Candida infections.

549 records 16/37 page Previous Next First page 上5页 1617181920 下5页 Last page